West Pharmaceutical Services (WST) Debt to Equity (2009 - 2026)

West Pharmaceutical Services has disclosed Debt to Equity across 18 years of filings, most recently posting $0.07 for Q1 2026.

• Debt to Equity for Q1 2026 came in at $0.07, down 10.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.07 (down 10.19% YoY), and the FY2025 annual result was $0.06, down 15.46% from the prior year.
• Debt to Equity came in at $0.07 for Q1 2026 at West Pharmaceutical Services, up from $0.06 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.09 in Q1 2022 to a low of $0.03 in Q4 2023.
• The 5-year median for Debt to Equity is $0.07 (2024), against an average of $0.07.
• Across the five-year window, Debt to Equity tumbled 67.18% in 2023 and surged 198.91% in 2024, its largest moves.
• West Pharmaceutical Services' Debt to Equity stood at $0.08 in 2022, then sank by 67.18% to $0.03 in 2023, then jumped by 198.91% to $0.08 in 2024, then dropped by 15.46% to $0.06 in 2025, then rose by 6.21% to $0.07 in 2026.
• The last three Debt to Equity figures came in at $0.07 (Q1 2026), $0.06 (Q4 2025), and $0.07 (Q3 2025), per Business Quant data.